Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 – CAPR

Core Points - A class action securities lawsuit has been filed against Capricor Therapeutics, Inc. for alleged securities fraud affecting investors between October 9, 2024, and July 10, 2025 [1][2] - The lawsuit claims that Capricor misled investors regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the Biologics License Application (BLA) for deramiocel, Capricor's stock price fell from $11.40 to $7.64 per share [2] Company Information - Capricor's lead product, deramiocel, was intended for the treatment of cardiomyopathy related to DMD, and the company had previously communicated positive expectations regarding its FDA approval [2] - The CRL indicated that Capricor did not meet the necessary requirements for substantial evidence of effectiveness and required additional clinical data [2] Legal Proceedings - Investors who suffered losses during the specified timeframe have until September 15, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require any out-of-pocket costs for class members [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]